330 related articles for article (PubMed ID: 29971584)
21. Radiographic patterns of muscle involvement in the idiopathic inflammatory myopathies.
Day JA; Bajic N; Gentili S; Patel S; Limaye V
Muscle Nerve; 2019 Nov; 60(5):549-557. PubMed ID: 31397909
[TBL] [Abstract][Full Text] [Related]
22. Long-term efficacy of adding intravenous immunoglobulins as treatment of refractory dysphagia related to myositis: a retrospective analysis.
Giannini M; Fiorella ML; Tampoia M; Girolamo F; Fornaro M; Amati A; Lia A; Abbracciavento L; D'Abbicco D; Iannone F
Rheumatology (Oxford); 2021 Mar; 60(3):1234-1242. PubMed ID: 32911543
[TBL] [Abstract][Full Text] [Related]
23. Dipeptidyl peptidase 4/CD26 expression in human idiopathic inflammatory myopathies reveals skeletal muscle injury and vascular inflammation.
De Lorenzo R; Monno A; Sciorati C; Lorenzetti I; Cavalli S; Bonomi F; Previtali SC; Rovere-Querini P
Clin Exp Rheumatol; 2022 Feb; 40(2):237-246. PubMed ID: 34796850
[TBL] [Abstract][Full Text] [Related]
24. Idiopathic inflammatory myopathies.
Dimachkie MM
J Neuroimmunol; 2011 Feb; 231(1-2):32-42. PubMed ID: 21093064
[TBL] [Abstract][Full Text] [Related]
25. Oral cyclophosphamide without corticosteroids to treat mucous membrane pemphigoid.
Munyangango EM; Le Roux-Villet C; Doan S; Pascal F; Soued I; Alexandre M; Heller M; Lièvre N; Aucouturier F; Caux F; Laroche L; Prost-Squarcioni C
Br J Dermatol; 2013 Feb; 168(2):381-90. PubMed ID: 22963186
[TBL] [Abstract][Full Text] [Related]
26. Pathophysiological Mechanisms and Treatment of Dermatomyositis and Immune Mediated Necrotizing Myopathies: A Focused Review.
Kamperman RG; van der Kooi AJ; de Visser M; Aronica E; Raaphorst J
Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35457124
[TBL] [Abstract][Full Text] [Related]
27. Recent clinical trials in idiopathic inflammatory myopathies.
Leclair V; Lundberg IE
Curr Opin Rheumatol; 2017 Nov; 29(6):652-659. PubMed ID: 28763333
[TBL] [Abstract][Full Text] [Related]
28. Evaluating disease status in idiopathic inflammatory myopathies with quantitative muscle ultrasound.
Tan JY; Tan CY; Yahya MA; Shahrizaila N; Goh KJ
Muscle Nerve; 2024 May; 69(5):597-603. PubMed ID: 38488306
[TBL] [Abstract][Full Text] [Related]
29. Long-term outcome of diffuse proliferative lupus glomerulonephritis treated with cyclophosphamide.
Mok CC; Ying KY; Ng WL; Lee KW; To CH; Lau CS; Wong RW; Au TC
Am J Med; 2006 Apr; 119(4):355.e25-33. PubMed ID: 16564783
[TBL] [Abstract][Full Text] [Related]
30. Idiopathic inflammatory myositis.
Tieu J; Lundberg IE; Limaye V
Best Pract Res Clin Rheumatol; 2016 Feb; 30(1):149-68. PubMed ID: 27421222
[TBL] [Abstract][Full Text] [Related]
31. Use of intravenous immunoglobulin therapy for myositis: an audit in South Australian patients.
Foreman C; Russo P; Davies N; Hissaria P; Proudman S; Hughes T; Limaye V
Intern Med J; 2017 Jan; 47(1):112-115. PubMed ID: 28076913
[TBL] [Abstract][Full Text] [Related]
32. Therapeutic options in autoimmune inflammatory myopathies (dermatomyositis, polymyositis, inclusion body myositis).
Pongratz D
J Neurol; 2006 Sep; 253 Suppl 5():V64-5. PubMed ID: 16998756
[TBL] [Abstract][Full Text] [Related]
33. Idiopathic inflammatory myopathies: current trends in pathogenesis, clinical features, and up-to-date treatment recommendations.
Ernste FC; Reed AM
Mayo Clin Proc; 2013 Jan; 88(1):83-105. PubMed ID: 23274022
[TBL] [Abstract][Full Text] [Related]
34. Use of methotrexate in inflammatory myopathies.
Fendler C; Braun J
Clin Exp Rheumatol; 2010; 28(5 Suppl 61):S164-7. PubMed ID: 21044453
[TBL] [Abstract][Full Text] [Related]
35. Biologics in refractory myositis: experience in juvenile vs. adult myositis; part II: emerging biologic and other therapies on the horizon.
Patwardhan A; Spencer CH
Pediatr Rheumatol Online J; 2019 Aug; 17(1):56. PubMed ID: 31429786
[TBL] [Abstract][Full Text] [Related]
36. Retrospective review of the clinical manifestations and outcomes in Puerto Ricans with idiopathic inflammatory myopathies.
Ríos G
J Clin Rheumatol; 2005 Jun; 11(3):153-6. PubMed ID: 16357735
[TBL] [Abstract][Full Text] [Related]
37. Dermatomyositis and Polymyositis in the Intensive Care Unit: A Single-Center Retrospective Cohort Study of 102 Patients.
Peng JM; Du B; Wang Q; Weng L; Hu XY; Wu CY; Shi Y
PLoS One; 2016; 11(4):e0154441. PubMed ID: 27115138
[TBL] [Abstract][Full Text] [Related]
38. Cyclophosphamide in combination with glucocorticoids for severe neuropsychiatric systemic lupus erythematosus: a retrospective, observational two-centre study.
Fanouriakis A; Pamfil C; Sidiropoulos P; Damian L; Flestea A; Gusetu G; Rednic S; Bertsias G; Boumpas DT
Lupus; 2016 May; 25(6):627-36. PubMed ID: 26692040
[TBL] [Abstract][Full Text] [Related]
39. [Therapeutic strategy in inflammatory myopathies (polymyositis, dermatomyositis, overlap myositis, and immune-mediated necrotizing myopathy)].
Tournadre A
Rev Med Interne; 2014 Jul; 35(7):466-71. PubMed ID: 24144868
[TBL] [Abstract][Full Text] [Related]
40. Current diagnosis and treatment of polymyositis and dermatomyositis.
Sasaki H; Kohsaka H
Mod Rheumatol; 2018 Nov; 28(6):913-921. PubMed ID: 29669460
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
